Virtual Library

Start Your Search

Carlos Chaib



Author of

  • +

    P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.01-91 - Treatment Patterns in Patients with Stage IIIB-IV NSCLC in Clinical Practice: Retrospective Analysis of a UK Trust Database (ID 13261)

      16:45 - 18:00  |  Author(s): Carlos Chaib

      • Abstract
      • Slides

      Background

      I-O Optimise is a new pan-European data platform developed to enable real-world insights into the management of thoracic malignancies. As part of this initiative, the current analysis reports the characteristics and treatment patterns for adult patients diagnosed with stage IIIB or IV NSCLC at Leeds Teaching Hospitals Trust (LTHT), hosting one of the largest integrated cancer centres in the UK.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Retrospective cohort study using longitudinal data already collected from electronic medical records at LTHT, including all adult patients diagnosed with stage IIIB-IV NSCLC between January 2007 and August 2017. Minimum follow-up was 6 months. Distinct lines of therapy (LoT) were identified using a clinically-verified algorithm based on the name and date of systemic anti-cancer therapy (SACT) administered and the gap between two treatments.

      4c3880bb027f159e801041b1021e88e8 Result

      Overall, 2119 patients were included. Mean age at diagnosis was 71.4 ± 11.2 years. Nearly one-third (32.7%) were clinically diagnosed without pathological confirmation (TABLE) and very few of these patients have SACT administration recorded. Following diagnosis, 648 patients (30.6%) received ≥1 LoT, 223 (10.5%) ≥2 LoT and 60 (2.8%) ≥3 LoT. Proportions of patients treated decreased with age (73.5% [25/34] aged 18-44 years; 52.7% [267/507] aged 45-64 years; 29.8% [310/1040] aged 65-79 years; 8.6% [46/538] aged 80+ years) and performance score (58.5% [387/662] PS0-1; 38.2% [158/414] PS2; 6.1% [52/848] PS3-4). Between the periods 2007-2011 and 2012-2017, increased proportions were treated (28.2% [263/933] and 32.5% [385/1186] respectively). Patient characteristics of the treated cohort and regimens administered for 1st and 2nd LoT are shown (TABLE).

      real onc_wclc 2018_submission_040518_table_hr.jpg

      8eea62084ca7e541d918e823422bd82e Conclusion

      Around 70% of this real-world cohort did not receive any SACT, and the administration of treatment was strongly associated with age and performance status. The changing availability of treatment options over time (including the emergence of immunotherapy) and survival outcomes by LoT will be presented in more detail for the cohort described.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.